Sigma Planning Corp Reduces Holdings in Kenvue Inc. (NYSE:KVUE)

Sigma Planning Corp decreased its position in Kenvue Inc. (NYSE:KVUE) by 59.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,052 shares of the company’s stock after selling 29,205 shares during the period. Sigma Planning Corp’s holdings in Kenvue were worth $432,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Empirical Finance LLC acquired a new position in shares of Kenvue in the 3rd quarter worth approximately $336,000. UniSuper Management Pty Ltd acquired a new stake in Kenvue during the 3rd quarter worth approximately $35,544,000. Citizens Business Bank acquired a new stake in Kenvue during the 3rd quarter worth approximately $2,507,000. Fifth Third Bancorp lifted its holdings in Kenvue by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after buying an additional 72,435 shares in the last quarter. Finally, Clearbridge Investments LLC raised its holdings in shares of Kenvue by 364.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock valued at $9,725,000 after purchasing an additional 380,071 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.8 %

KVUE stock opened at $18.86 on Friday. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The company has a fifty day moving average of $19.84 and a 200-day moving average of $20.13.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Research analysts forecast that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Analysts Set New Price Targets

A number of research analysts recently commented on KVUE shares. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. Royal Bank of Canada dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.